New chemo cocktail shows promise for rare blood cancer in younger patients
NCT ID NCT02858804
First seen Feb 16, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tested a two-part chemotherapy regimen (EDOCH alternating with DHAP) with or without the targeted drug rituximab in 55 younger adults (age 65 or under) newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach improves how long patients live without the cancer getting worse. After treatment, some patients received maintenance therapy to help keep the cancer in check. The trial has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.